Skip to content

Contact +44 (0) 20 7060 7474 email us

Bayer

Bayer Schering Pharma AG: PharmaVitae Profile

 

Publication Date July 2009
Publisher Datamonitor
Product Type Report
Pages 127
ISBN Number not applicable
Product Code DAT01754

Price

£3,765.00
approximately: $5,701 | €4,202

pdf

Buy Now

print £3,830 ($5,799 | €4,275)

Buy Now

Order above formats by FAX

Order by Fax

Summary

Introduction

This analysis examines the historical and forecast performance for Bayer Schering in the prescription pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information

Reasons to Purchase

  • Benchmark Bayer Schering Pharma's performance against key rivals in the ethical pharmaceutical sector
  • Analyse how Bayer's acquisition of Schering AG in 2006 has notably enhanced the company's HealthCare division
  • Assess how an increased healthcare focus and merger-related synergies will drive an increase in operating profit at an 8.4% CAGR over 200814

Contents

  • ABOUT DATAMONITOR HEALTHCARE
  • About the PharmaVitae team
  • Chapter 1 About this profile
    • PharmaVitae Explorer database
  • Chapter structure
    • Executive summary
    • Quarterly news update
    • Company introduction
    • Company sales
    • Company financials
    • Key products and competitors
    • Data sourcing
    • Sales data
    • Analyst consensus
  • Chapter 2 Executive summary
    • Key findings
    • Prescription pharmaceutical sales and growth rate performance, 2002-14
    • Financial performance, 2002-14
    • Bayer: PharmaVitae forecasts at a glance
    • Strategic insight
    • Bayer's diversified structure is unusual within Big Pharma peer set
    • Weak revenue performance over 2001-03 initiates restructuring strategy
    • Bayer's restructuring efforts have proved successful
    • Bayer's portfolio to drive prescription pharma growth over 2008-14
    • SWOT analysis
    • Strengths
    • Weaknesses
    • Opportunities
    • Threats
    • Table of figures
  • Chapter 3 Quarterly news update
    • Product developments
    • Deals and alliances
    • Product deals
    • Technology deals
    • M&A activity
    • Company announcements
    • Future product milestones
  • Chapter 4 Company introduction
    • Key findings
    • Background
    • Key corporate developments
    • Current corporate structure
    • Bayer Healthcare
    • Bayer MaterialScience
    • Bayer CropScience
    • Bayer Healthcare business unit structure
    • Prescription pharmaceuticals
    • Consumer care
    • Animal health
    • Medical care (Diagnostics)
    • M&A history
    • Acquisition of Roche Consumer Health AG (RCH)
    • Lanxess AG Spin-off
    • Divestment of US Plasma Products
    • Acquisition of Schering AG
    • Recent M&A promotes Bayer's healthcare focus
    • Divestment of Diagnostics Division
    • Divestment of H.C. Starck and Wolff Walsrode
    • Acquisition of Possis Medical and Sagmel Inc
    • M&A strategy
  • Chapter 5 Company sales
    • Key findings
    • Prescription pharmaceutical sales and growth rate analysis, 2002-14
    • Product analysis
    • Product analysis, 2002-08
    • Product analysis, 2008-14
    • Therapy area analysis
    • Geographic analysis
    • Launch/core/expiry analysis
    • Explanation of launch/core/expiry analysis
    • Launch analysis, 2008-14
    • Core analysis, 2008-14
    • Expiry analysis, 2008-14
    • Launch/core/expiry configuration, 2008-14
    • Molecule type analysis
    • Externalization analysis
  • Chapter 6 Company financials
    • Key findings
    • Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08
    • Operating costs and profit analysis
    • Operating costs and profit analysis, 2002-08
    • Operating cost ratio and profit margin analysis, 2002-08
    • Operating cost ratio and profit margin analysis, 2008-14
    • Operating costs and profit analysis, 2008-14
  • Chapter 7 Key products and competitors
    • Key findings
    • Overview
    • Oncology
    • Nexavar
    • Overview
    • Sales forecast
    • Nexavar encounters strong competition in the RCC market
    • HCC market to offer better sales potential
    • Further indication broadening will boost sales growth
    • Cardiovascular
    • Xarelto
    • Overview
    • Sales forecast
    • A replacement for Warfarin?
    • Pradaxa expected to take first-to-market advantage
    • Adalat
    • Overview
    • Sales forecast
    • Extended release formulation rejuvenates brand
    • The impact of genericization
    • Rise of the ARB class
    • Hematology
    • Kogenate
    • Overview
    • Sales forecast
    • Delivery device is key contributor to growth of Kogenate franchise
    • Growth of hemophilia market will continue to drive Kogenate sales growth
    • Key competitors
    • Patent challenge
    • PEGylated formulation offers potential upside
    • Genitourinary
    • Mirena
    • Overview
    • Sales forecast
    • An alternative to sterilization
    • Launch in the Japanese market
    • Key competitors
    • Levitra
    • Overview
    • Sales forecast
    • Key competitors
    • PDE-5 safety concerns
    • Levitra licensing agreements
    • Yaz
    • Overview
    • Sales forecast
    • The Impact of Yasmin's invalidated patent protection
    • New market launches
    • Key competitors
    • The switch from Yasmin to Yaz
    • Yasmin
    • Overview
    • Sales forecast
    • Yasmin: a historical growth driver
    • Yasmin patent invalidated following challenge from Barr Pharmaceuticals
    • The impact of generics
    • Key competitors
    • Central nervous system
    • Betaferon
    • Overview
    • Sales forecast
    • Betaferon: a success story despite initial challenges
    • Novartis agreement
    • Key competitors
    • MabCampath (MS)
    • Overview
    • Sales forecast
    • MabCampath divested to Genzyme in 2009, but interest in MS indication remains
    • Launch anticipated in 2012
    • Infectious disease
    • Avelox
    • Overview
    • Sales forecast
    • Antibiotics market encounters growing patient resistance
    • Key competitors
    • Avelox in a good position despite increasing genericization
    • Avelox patent challenge: generic moxifloxacin not expected by 2014
    • Endocrine, metabolic and genetic disorders
    • Glucobay
    • Overview
    • Sales forecast
    • The poor performance of the AGI class
    • Key competitors
    • Other
    • VEGF Trap-Eye
    • Overview
    • Sales forecast
  • Chapter 8 Appendix
    • R&D pipeline
    • References
    • Abbreviations
    • Exchange rates
    • About Datamonitor
    • About Datamonitor Healthcare
    • Datamonitor consulting
    • Disclaimer
    • Table 1: Bayer - PharmaVitae forecasts at a glance
    • Table 2: Bayer key product developments, 2009
    • Table 3: Bayer product deals and alliances, 2009
    • Table 4: Bayer technology deals and alliances, 2009
    • Table 5: Bayer M&A activity, 2009
    • Table 6: Bayer company announcements, 2009
    • Table 7: Bayer future product milestones, 2009-11
    • Table 8: Bayer product portfolio overview ($m), 2002-08
    • Table 9: Bayer product portfolio overview ($m), 2008-14
    • Table 10: Bayer prescription pharmaceutical sales by therapy area ($m), 2008-14
    • Table 11: Bayer prescription pharmaceutical sales by geographic region ($m), 2008-14
    • Table 12: Bayer launch portfolio overview ($m), 2008-14
    • Table 13: Bayer core portfolio overview ($m), 2008-14
    • Table 14: Bayer expiry portfolio overview ($m), 2008-14
    • Table 15: Bayer prescription pharmaceutical sales by molecule type ($m), 2008-14
    • Table 16: Bayer prescription pharmaceutical sales by source ($m), 2008-14
    • Table 17: Total Bayer sales by business unit ($m), 2002-08
    • Table 18: Bayer operating revenue/cost analysis ($m), 2002-08
    • Table 19: Bayer operating cost ratio analysis (% of total revenues), 2002-08
    • Table 20: Bayer operating cost ratio analysis (% of total revenues), 2008-14
    • Table 21: Bayer operating revenue/cost analysis ($m), 2008-14
    • Table 22: Key products overview
    • Table 23: Nexavar: overview
    • Table 24: Nexavar: sales forecast ($m), 2008-14
    • Table 25: Xarelto: overview
    • Table 26: Xarelto: sales forecast ($m), 2008-14
    • Table 27: Adalat: overview
    • Table 28: Adalat: sales forecast ($m), 2008-14
    • Table 29: Kogenate: overview
    • Table 30: Kogenate: sales forecast ($m), 2008-14
    • Table 31: Mirena: overview
    • Table 32: Mirena: sales forecast ($m), 2008-14
    • Table 33: Key players in the oral contraceptives market, 2008-14
    • Table 34: Levitra: overview
    • Table 35: Levitra: sales forecast ($m), 2008-14
    • Table 36: Yaz: overview
    • Table 37: Yaz: sales forecast ($m), 2008-14
    • Table 38: Yasmin: overview
    • Table 39: Yasmin: sales forecast ($m), 2008-14
    • Table 40: Betaferon: overview
    • Table 41: Betaferon: sales forecast ($m), 2008-14
    • Table 42: MabCampath (MS): overview
    • Table 43: MabCampath (MS): sales forecast ($m), 2008-14
    • Table 44: Avelox: overview
    • Table 45: Avelox: sales forecast ($m), 2008-14
    • Table 46: Key players in the antibiotics market, 2008
    • Table 47: Glucobay: overview
    • Table 48: Glucobay: sales forecast ($m), 2008-14
    • Table 49: VEGF Trap-Eye: overview
    • Table 50: VEGF Trap-Eye: sales forecast ($m), 2008-14
    • Table 51: Bayer's R&D new molecular entity pipeline (Phase I-registration)
    • Table 52: Bayer's R&D life cycle management pipeline (Phase I-registration)
    • Table 53: Exchange rates, 2009
  • List of Figures
    • Figure 1: The PharmaVitae Explorer
    • Figure 2: Bayer prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14
    • Figure 3: Bayer's financial performance ($m), 2002-14
    • Figure 4: Bayer AG corporate structure, 2002-14
    • Figure 5: Bayer AG, key acquisitions and divestments, 2001-08
    • Figure 6: Big Pharma peer set: rank by prescription pharma focus as % of total revenue, 2008 and 2014
    • Figure 7: Bayer Schering Pharma prescription pharmaceutical sales by source ($m), 2002-14
    • Figure 8: Bayer SWOT analysis
    • Figure 9: Current corporate structure
    • Figure 10: Bayer Healthcare business unit structure by revenues, 2002-08, ($m)
    • Figure 11: Bayer key M&A and divestment events, 2002-08
    • Figure 12: Bayer prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14
    • Figure 13: Key product sales ($m), 2002-14
    • Figure 14: Bayer key sales growth drivers and resistors ($m), 2002-08
    • Figure 15: Bayer key sales growth drivers and resistors ($m), 2008-14
    • Figure 16: Bayer prescription pharmaceutical sales by therapy area ($m), 2002-14
    • Figure 17: Bayer prescription pharmaceutical sales by geographic region ($m), 2002-14
    • Figure 18: Bayer launch/core/expiry configuration ($m), 2008-14
    • Figure 19: Bayer prescription pharmaceutical sales by molecule type ($m), 2002-14
    • Figure 20: Bayer prescription pharmaceutical sales by source ($m), 2002-14
    • Figure 21: Bayer operating revenue/cost analysis ($m), 2002-14